Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC

Wenfeng Fang; Lin Wu; Xiangjiao Meng; Yu Yao; Wei Zuo; Wenxiu Yao; Yanyan Xie; Yu Zhang; Jiuwei Cui; Yongchang Zhang; Xingya Li; Wu Zhuang; Jian Fang; Qiming Wang; Wei Jiang; Kai Li; Yuju Bai; Yongzhong Luo; Fang Ma; Yan Yu; Wei Zheng; Zhentian Liu; Bin Yang; Rui Ma; Yong Fang; Runxiang Yang; Liyan Jiang; Jie Hu; Jiacheng Yang; Yina Diao; Xiaoping Jin; Junyou Ge; Yun-Peng Yang; Li Zhang

doi:10.1056/nejmoa2512071

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In patients with EGFR-mutated advanced or metastatic NSCLC that had progressed after previous EGFR-TKI therapy, progression-free survival and overall survival outcomes were significantly better with sac-TMT than with platinum-based chemotherapy. (Funded by Sichuan Kelun-Biotech Biopharmaceutical; OptiTROP-Lung04 ClinicalTrials.gov number, NCT05870319.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fang et al. (2025) studied this question.

synapsesocial.com/papers/69d97dbfc7f0c3ae80a3daf0 https://doi.org/10.1056/nejmoa2512071

View at Publisher

Ask AI

Bookmark

Share

Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading